United States: HHS Releases Highly Anticipated Proposal To Modernize U.S. Human Subjects Research Protections

In a notice of proposed rulemaking (NPRM) released September 2, 2015, the U.S. Department of Health and Human Services (HHS), through the Office for Human Research Protections (OHRP) and 15 other federal departments and agencies, issued long-awaited proposed amendments to the Federal Policy for the Protection of Human Subjects (the Common Rule). HHS' stated goal of these significant and extensive amendments is to align the Common Rule with changes to the research and privacy landscape since the original Common Rule was promulgated in 1991, and to otherwise strengthen and modernize the Common Rule.

As proposed, the NPRM would materially alter how research is designed and conducted, and would meaningfully change how genomic and tissue-related research is structured. In addition, the Common Rule currently only applies to federally funded or supported research (unless an institution has made an election in its Federalwide Assurance to conduct human subjects research in accordance with the Common Rule regardless of funding). In a meaningful expansion of its jurisdictional scope the NPRM proposes to subject all non-FDA regulated, non-exempted and non-excluded human subjects research, irrespective of funding source for a particular research study, conducted at a U.S. institution that receives federal support for human subjects research generally to the Common Rule. The proposed changes in the NPRM may also have a significant impact on current research and quality assurance practices.

Given the NPRM's proposal to significantly expand the scope of the Common Rule and the other extensive changes it proposes, the NPRM is of interest to a wide array of stakeholders who need to be aware of HHS' trajectory on these proposed changes and who should consider participating in submitting public comments regarding the proposed changes. Such comments are due December 7, 2015.

History and Overview of the NPRM

On July 26, 2011, the Office of the Secretary of HHS, in coordination with the Executive Office of the President's Office of Science and Technology Policy (OSTP), published an advanced notice of proposed rulemaking (ANPRM) that solicited comments regarding modernizing and revising current human subjects protections. 76 Fed. Reg. 44,512 (July 26, 2011). The ANPRM's proposals for significant changes to the Common Rule prompted strong reactions. Many of the striking proposals discussed in the ANPRM have carried over to the NPRM, and comments submitted in response to the ANPRM and subsequent guidance in related areas have prompted additional new proposals in the NPRM.

The NPRM proposes a series of major changes to the Common Rule, including changes to its overall jurisdictional scope; requirements relating to secondary use of biospecimens and individually identifiable information; and the research review and oversight process. Key changes are summarized below.

  • Jurisdiction. As proposed in the ANPRM, the NPRM would extend the Common Rule's jurisdiction to trials conducted at U.S. institutions receiving federal support for non-FDA (Food and Drug Administration), "non-exempt and non-excluded human subjects research, regardless of the funding source of the specific clinical trial" (emphasis added).
  • Regulating biospecimens under the Common Rule. Although the NPRM notes that a majority of the commenters to the ANPRM opposed such a change, the NPRM proposes to include biospecimens in the definition of a "human subject" regardless of whether the biospecimens contain identifiable information, except under very limited circumstances. This requirement would apply only prospectively, and would be delayed in its implementation until three years after the publication of the final rule. Under the current regulations, a biospecimen constitutes a "human subject" if the data annotating that sample is determined to be individually identifiable. The role of identifiability in determining whether use of data or tissue constitutes research involving a human subject is a foundational definitional divide that finds residence not just in the Common Rule, but also in the Health Insurance Portability and Accountability Act (HIPAA) and many state laws. The NPRM's proposal is a significant departure from this historical mainstay. In describing the change, OHRP suggests that it will balance public preferences for autonomy and will "avoid[] codifying any given interpretation of the quickly evolving debates regarding whether certain analytical results (e.g., decoding the whole genome) should be considered to yield identifiable data."
    • Alternative proposals for regulating biospecimens. Although the NPRM proposes to define all biospecimen research as human subjects research under the Common Rule, the NPRM also solicits comments on two alternative proposals for how to extend the scope of the Common Rule with respect to biospecimens.
      • One alternative is to change the definition of a "human subject" to specifically include individuals from whom data is generated from whole genome sequencing (WGS). Under this alternative proposal, the Common Rule would apply to any research that would generate WGS data and the use of any of the data generated from WGS, and to secondary research uses of any part of the WGS data (this is referred to as "Alternative A" in the NPRM).
      • Another proposal would classify biospecimens, and certain information generated from biospecimens used in particular technologies (referred to in the NPRM as "bio-unique information"), as relating to a "human subject" for purposes of the Common Rule. Only information derived from specific technologies listed on a newly created "Secretary's List" would meet the definition of "bio-unique information." For example, the NPRM notes that if WGS is a technology listed on the Secretary's List, then WGS research using biospecimens would be subject to the Common Rule as human subjects research, regardless of the researcher's ability to identify the biospecimen's source (this is referred to as "Alternative B" in the NPRM).

        HHS solicits comments regarding the above options for how it would expand the definition of a "human subject."
  • Secondary use of biospecimens and private information. Regulating the secondary research use of biospecimens and private information is also a central focus of the NPRM. "Secondary use" means the use of data or biospecimens for a purpose different from the purpose for which the data or biospecimen was originally created or collected (e.g., using for research tissue samples that were collected for and left over from clinical care). The NPRM points to recent studies showing that most people prefer to have control over secondary uses of their biospecimens and data, and considers "continuing to allow secondary research with biospecimens collected without consent" an "untenable position" that is out of line with most individuals' wishes.
    • Because, as described above, the NPRM would expand the scope of the Common Rule to include all biospecimens, the NPRM also proposes changes designed to continue to facilitate biospecimen research. In particular, the NPRM proposes to allow researchers to obtain a one-time broad consent for the storage or maintenance of biospecimens (as well as identifiable private information) for secondary research use and for the use of such stored material for subsequent individual research studies. Nonetheless, this consent requirement will likely present a number of operational and record keeping challenges, especially if individuals wish to give consent for some but not all use cases
    • In addition, though the NPRM proposes to consider secondary uses of biospecimens as human subjects research, it also proposes an exclusion applicable to the secondary use of non-identifiable biospecimens for research that generates information already known about the individual. This would include validation tests and research to develop specific diagnostic tests. The NPRM proposes an exemption for the storage or maintenance for secondary research use of properly obtained biospecimens or identifiable private information. This exemption would still be subject to certain requirements, such as certain recordkeeping requirements and compliance with the new proposed privacy requirements. The NPRM also proposes an exemption for research involving the use of biospecimens or identifiable private information that have been specifically stored or maintained to allow for potential future secondary research uses. The NPRM includes another exemption for the secondary research use of some identifiable private information acquired for non-research purposes.
  • Informed consent requirements. The NPRM proposes changes to the organization and presentation of information to subjects and the elements of informed consent. The NPRM also adds new elements of consent, which are required for certain types of research. Notably, for research involving the collection of identifiable private information, subjects must be notified if their non-identified information could be used for future research without additional consent. The NPRM would also create a "Secretary's Template" that researchers could use to collect broad consent from subjects for the secondary research use of biospecimens and identifiable private information. If researchers choose not to use the template, such broad consent must include certain specific elements proposed in the NPRM. Another notable proposal would require consent documents for trials conducted or supported by a Common Rule department or agency to be posted on a publicly available federal website within 60 days after the close of the trial's recruitment.
  • Informed consent waiver criteria. The NPRM proposes a number of changes relating to the requirements for institutional review board (IRB) waiver of the informed consent requirements.
    • Because, as described above, the NPRM would require researchers to obtain informed consent to bank biospecimens for secondary research use (even if the biospecimens are annotated with only de-identified information), the NPRM proposes to impose a new waiver prohibition for IRBs. If an individual was asked and specifically refused to sign a broad consent to allow the storage or maintenance of his/her biospecimens (or identifiable private information) for secondary research uses, IRBs would not be permitted to waive this consent requirement for either the storage or maintenance or for the secondary research use as a way to circumvent that refusal.
    • The NPRM proposes additional new waiver criteria for research involving biospecimens. These criteria would permit IRBs to waive or amend the consent requirement for biospecimen research only in "extremely rare" circumstances, such as when the research "could not be conducted with other biospecimens for which informed consent was or could be obtained."
    • The NPRM establishes new waiver criteria modeled after the HIPAA Privacy Rule requirements for studies that use identifiable biospecimens or identifiable information in particular. Specifically, the NPRM proposes a requirement that the research "could not be practicably carried out without accessing or using identifiers" (emphasis added). The NPRM also clarifies how HHS interprets the term "practicably" in waiving informed consent for all other research studies (i.e., when the research cannot be practicably carried out without the waiver of consent).
  • New exclusion regulations. The NPRM proposes to include a new list of 11 specific activities that would be "excluded" from the Common Rule's requirements. Such activities include but are not limited to: (i) certain quality assurance or improvement activities involving the implementation of an accepted practice to improve the quality or delivery of health care; (ii) certain activities covered by the HIPAA Privacy Rule; (iii) the secondary research use of non-identifiable biospecimens designed only to generate information about an individual that is already known; and (iv) certain collection and analysis of data and biospecimens for an institution's own internal operational monitoring and program improvement purposes. In order to qualify as an excluded activity under (iv) above, the data or biospecimen collection and analysis must be either be: (a) limited to the use of data or biospecimens originally collected for a purpose other than the current proposed activity, or (b) obtained through oral or written communications, like surveys or interviews, with individuals.
    • The proposed exclusions are notable for their scope and nature and raise a number of questions. Proposed exclusion category (iv) above is unusual in its incorporation of biospecimen use in activities that otherwise appear to be similar to health care operations activities. This category also appears to cover activities similar to those covered by the quality assurance and improvement exclusion (exclusion (i) above). The quality assurance exclusion, in turn, would not cover the evaluation of the accepted quality assurance or quality improvement practice itself, even if the purpose of the evaluation arguably is not to develop "generalizable knowledge" (i.e., the purpose is not research). It is unclear whether proposed exclusion (iv) is intended to encompass some or all of the evaluation activities that the NPRM carves out of the quality assurance exclusion. Another source of potential confusion is the NPRM's discussion of the HIPAA Privacy Rule exclusion (exclusion (ii) above), which explicitly references only covered entities and is silent on activities of business associates.
  • New exemption regulations and a new exemption tool. The NPRM also proposes to exempt eight categories of research from certain Common Rule requirements and to make available a determination tool to assist researchers in determining whether their trial is exempt. This tool would act as a "safe harbor mechanism"—assuming researchers included correct and accurate information, federal regulators would consider the tool's determination of exempt status to be appropriate.
  • Data security and information protection standards. The NPRM proposes to generally require researchers to "implement reasonable safeguards for protecting against risks to the security or integrity of biospecimens or identifiable private information." The NPRM proposes several options from which researchers and institutions may choose to satisfy this obligation, including a list of specific measures published by the HHS Secretary, complying with HIPAA as otherwise required of the institution or investigator, and the requirements of other statutes such as the Family Educational Rights and Privacy Act (FERPA). Specific to biospecimens and identifiable private information, OHRP proposes to limit the re-disclosure of biospecimens and identifiable private information that were obtained for research purposes to four specific purposes (such as research regulated under the Common Rule).
  • Single IRB / changes to IRB review. Under the proposed rules, all U.S. institutions engaged in cooperative research must rely on a single IRB as their reviewing IRB for that study, with limited exceptions. The NPRM also changes the default for expedited review for minimum risk studies, requiring expedited review unless the reviewers determine the study is more than minimal risk (in contrast with the current requirement, where an IRB may use expedited review only if the reviewer determines the study is no more than minimal risk). The NPRM would also eliminate continuing review for minimal risk studies unless the reviewer documents why continuing review should take place, and for research involving certain secondary research with information and biospecimens.
  • Harmonization. The NPRM notes that the FDA intends to modify its separate human subjects protection regulations in light of the NPRM, as appropriate. As seen above, the NPRM also attempts to cross-walk to certain HIPAA standards and concepts. These attempts, however, fall far short of harmonizing the Common Rule with HIPAA's research-related requirements, and leave many unanswered questions regarding the interaction between these two rules moving forward.

HHS is soliciting comments on the NPRM, which are due December 7, 2015. HHS intends to release several webinars regarding the NPRM, and will hold a town hall-style meeting on the draft in Washington, D.C. in October. A copy of the NPRM can be found here. In the interim, stakeholders should continue to monitor NPRM-related releases from HHS that may have an impact on their research practices.

HHS Releases Highly Anticipated Proposal To Modernize U.S. Human Subjects Research Protections

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions